Surgical robotics company, PROCEPT® BioRobotics, has announced that Blue Cross Blue Shield of Massachusetts and EmblemHealth are now providing insurance coverage for Aquablation therapy delivered by the AquaBeam® Robotic System for the treatment of benign prostatic hyperplasia (BPH).
Blue Cross Blue Shield of Massachusetts (BCBS MA) is an Independent Licensee of the Blue Cross and Blue Shield Association, serves nearly three million members and is rated among the nation’s best health plans for member satisfaction and quality. Headquartered in Boston, MA for more than 80 years, the company has worked hard to achieve their mission of providing access to high-quality, affordable health care for the individuals, families, and businesses they serve.
EmblemHealth provides insurance plans, primary and specialty care, and wellness solutions to more than three million members in the New York tristate area. EmblemHealth started back in the 1930s, at the height of the Great Depression and after 80 years, their mission is still the same: to create healthier futures for their customers and communities.
“Massachusetts and the New York tristate area are home to some of the best healthcare facilities in the northeast. BCBS MA and EmblemHealth’s commitment to provide Aquablation therapy to their members aligns with their missions to provide high-quality healthcare,” said Reza Zadno, president and chief executive officer of PROCEPT BioRobotics. “These coverage decisions further validate the clinical value of Aquablation therapy and provide more patients access to the only BPH surgical treatment with proven clinical outcomes, independent of the size or the shape of the prostate, and a reduced risk of sexual side effects.”
“We are thrilled with BCBS MA positive coverage of Aquablation therapy as it is the optimal treatment for many men suffering from symptoms of BPH,” said Arthur Mourtzinos, MD, Urologist at Lahey Hospital & Medical Center. “The real-time multi-dimensional views of the prostate and contour mapping provide a truly personalized treatment for every man regardless of prostate shape or size.”
This announcement compliments positive coverage positions from Medicare, Anthem and Humana, expanding access to Aquablation therapy to over 100M covered lives in the United States.